Back to today’s briefing

Story perspectives

Trump's Tariff Plan Threatens Biotech Firms' Stability

3/30/2025

43 3

Summary

Story summary

President Trump aims to impose tariffs on imported pharmaceuticals to boost U.S. manufacturing.
Biotech firms expect rising costs and stock declines, as 90% depend on imported components.
Vertex Pharmaceuticals has minimal tariff exposure, while Amgen and Biogen will be significantly affected.
Industry leaders emphasize the necessity for incentives to enhance domestic biotech manufacturing.

1 of 1

Story summary

President Trump aims to impose tariffs on imported pharmaceuticals to boost U.S. manufacturing.
Biotech firms expect rising costs and stock declines, as 90% depend on imported components.
Vertex Pharmaceuticals has minimal tariff exposure, while Amgen and Biogen will be significantly affected.
Industry leaders emphasize the necessity for incentives to enhance domestic biotech manufacturing.